Analytical Data
-
Gene name
SPG21
-
简介
The SPG21 protein acts as a negative regulator in CD4-dependent T cell activation, suggesting a potential role in the regulation of immune responses. By interacting directly with CD4, it affects key components of the T cell activation pathway. SPG21 Protein, Mouse (sf9, His) is the recombinant mouse-derived SPG21 protein, expressed by Sf9 insect cells , with N-His labeled tag.
- Application
-
Alternative Names
Maspardin; Acid cluster protein 33; ACP33; BM-019; GL010; Spastic paraplegia 21 protein
-
Species
Mouse
-
Source
Baculovirus
-
Tag
N-6*His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q9CQC8-1
-
Expression Region
M1-P308
-
Protein Length
Full Length of Isoform-1
-
Molecular Weight
35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SPG21, also known as Spastic Paraplegia 21, is a gene associated with hereditary spastic paraplegia (HSP), a group of neurodegenerative disorders characterized by progressive weakness and stiffness of the lower limbs. The SPG21 gene encodes a protein called spatacsin, which is believed to play a crucial role in maintaining neuronal function and membrane integrity. Mutations in the SPG21 gene lead to the accumulation of damaged organelles and impaired autophagy, ultimately resulting in neurodegeneration and clinical symptoms of HSP. Research into the structure and function of SPG21 recombinant protein is essential for understanding the underlying mechanisms of the disease and developing potential therapeutic strategies. Scientists have been focusing on producing and characterizing SPG21 recombinant protein to investigate its interactions with other cellular components and its role in cellular processes. By utilizing advanced techniques such as X-ray crystallography and cryo-electron microscopy, researchers aim to elucidate the protein's three-dimensional structure and gain insights into how specific mutations affect its functionality. Understanding these molecular details is crucial for uncovering the pathophysiology of HSP caused by SPG21 mutations and may pave the way for targeted treatments, such as gene therapy or small molecules that can modulate the cellular pathways affected by spatacsin dysfunction. Therefore, the study of SPG21 recombinant protein not only enhances our comprehension of hereditary spastic paraplegia but also represents a promising avenue for future research and therapeutic intervention in this debilitating condition.
